BIVI: Bezisterim showed significant benefit in symptomatic Long COVID patients and is advancing to Phase 3
Bezisterim demonstrated statistically significant improvements in fatigue, post-exertional malaise, and cognitive impairment among Long COVID patients with high baseline symptom burden, with a safety profile similar to placebo. All advisors recommend advancing to Phase 3 trials.Original document: B…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.